The plasimongen activator (PA)-plasmin cascade plays a central role in processes involving limited protein breakdown, including dissolving blood clots, tissue remodeling, and tumor cell invasion. Type-1 PA-inhibitor (PAl-1) is the major physiologic regulator of plasminogen activation and its expression is tightly regulated. Our laboratory is investigating the molecular mechanisms by which hormones and growth factors regulate expression of the PAl-1 gene.
1963 Harvard Medical School, M.D.
1959 University of Oxford, M.A.
1957 Oberlin College, B.A.
1995-00 Journal of Biological Chemistry
2002 - NIH Recombinant DNA Advisory Committee
Honors and Awards
2005 Kaiser-Permanente Award for Excellence in Pre-clinical Teaching
1995 Keeley Visiting Fellowship, Wadham College, University of Oxford
1988-95 MERIT Award, National Cancer Institute
1986- Who's Who in America
1975-79 Faculty Research Award, American Cancer Society
Gelehrter TD, Collins FS, Ginsburg D: Principles of Medical Genetics, 2nd ed. Baltimore, Lippincott Williams and Wilkins, 1998. (3rd edition in progress)
Song C-Z, Tian X, Gelehrter TD. Glucocorticoid receptor inhibits transforming growth factor-ß signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci USA 1999; 96:11776-11781.
Heaton JH, Dlakic W, Dlakic M, Gelehrter TD: Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the type-1 plasminogen activator inhibitor. J Biol Chem 2001; 276:3341-3347.
Heaton JH, Dlakic WM, Gelehrter TD: Posttranscriptional regulation of PAl-1 gene expression. Thromb Haemost 2003; 89: 949-66.
Li G, Wang S, Gelehrter TD: Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor- β action. J Biol Chem 2003; 278: 41779-88